Literature DB >> 2400225

Pseudomonas cepacia: a new pathogen in patients with cystic fibrosis referred to a large centre in the United Kingdom.

E J Simmonds1, S P Conway, A T Ghoneim, H Ross, J M Littlewood.   

Abstract

Pseudomonas cepacia infection has become increasingly common among patients with cystic fibrosis in North America. In a large cystic fibrosis centre in the United Kingdom 11 cases have been identified during the last six years, with a maximum prevalence of 7% in 1988. Three patients have died, two of whom deteriorated rapidly shortly after acquisition of the organism despite intensive treatment with appropriate antibiotics. Analysis of possible causes of the increase in P cepacia infection suggested that neither patient to patient transmission nor the use of nebulised antibiotics was associated with an increased risk of infection.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2400225      PMCID: PMC1792469          DOI: 10.1136/adc.65.8.874

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  13 in total

1.  Long-term study of one hundred five patients with cystic fibrosis; studies made over a five- to fourteen-year period.

Authors:  H SHWACHMAN; L L KULCZYCKI
Journal:  AMA J Dis Child       Date:  1958-07

2.  Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis.

Authors:  M E Hodson; A R Penketh; J C Batten
Journal:  Lancet       Date:  1981-11-21       Impact factor: 79.321

3.  Ribotype analysis of Pseudomonas cepacia from cystic fibrosis treatment centers.

Authors:  J J LiPuma; J E Mortensen; S E Dasen; T D Edlind; D V Schidlow; J L Burns; T L Stull
Journal:  J Pediatr       Date:  1988-11       Impact factor: 4.406

4.  Nebulised colomycin for early pseudomonas colonisation in cystic fibrosis.

Authors:  J M Littlewood; M G Miller; A T Ghoneim; C H Ramsden
Journal:  Lancet       Date:  1985-04-13       Impact factor: 79.321

Review 5.  The epidemiology of Pseudomonas cepacia in patients with cystic fibrosis.

Authors:  O C Tablan; W J Martone; W R Jarvis
Journal:  Eur J Epidemiol       Date:  1987-12       Impact factor: 8.082

6.  Pseudomonas cepacia: decrease in colonization in patients with cystic fibrosis.

Authors:  M J Thomassen; C A Demko; C F Doershuk; R C Stern; J D Klinger
Journal:  Am Rev Respir Dis       Date:  1986-10

7.  Pseudomonas cepacia colonization among patients with cystic fibrosis. A new opportunist.

Authors:  M J Thomassen; C A Demko; J D Klinger; R C Stern
Journal:  Am Rev Respir Dis       Date:  1985-05

8.  Colonization of the respiratory tract with Pseudomonas cepacia in cystic fibrosis. Risk factors and outcomes.

Authors:  O C Tablan; W J Martone; C F Doershuk; R C Stern; M J Thomassen; J D Klinger; J W White; L A Carson; W R Jarvis
Journal:  Chest       Date:  1987-04       Impact factor: 9.410

9.  Pseudomonas cepacia colonization in patients with cystic fibrosis: risk factors and clinical outcome.

Authors:  O C Tablan; T L Chorba; D V Schidlow; J W White; K A Hardy; P H Gilligan; W M Morgan; L A Carson; W J Martone; J M Jason
Journal:  J Pediatr       Date:  1985-09       Impact factor: 4.406

10.  Pseudomonas cepacia in the hospital setting: lack of transmission between cystic fibrosis patients.

Authors:  K A Hardy; K L McGowan; M C Fisher; D V Schidlow
Journal:  J Pediatr       Date:  1986-07       Impact factor: 4.406

View more
  19 in total

1.  Pseudomonas and Aeromonas isolates from domestic reptiles and study of their antimicrobial in vitro sensitivity.

Authors:  V V Ebani; F Fratini; M Ampola; E Rizzo; D Cerri; E Andreani
Journal:  Vet Res Commun       Date:  2008-09       Impact factor: 2.459

2.  Pseudomonas cepacia in cystic fibrosis.

Authors:  D E Stableforth; D L Smith
Journal:  Thorax       Date:  1994-07       Impact factor: 9.139

Review 3.  Microbiology of cystic fibrosis lung infections: themes and issues.

Authors:  J R Govan; J W Nelson
Journal:  J R Soc Med       Date:  1993       Impact factor: 5.344

4.  Burkholderia cepacia and cystic fibrosis: do natural environments present a potential hazard?

Authors:  S L Butler; C J Doherty; J E Hughes; J W Nelson; J R Govan
Journal:  J Clin Microbiol       Date:  1995-04       Impact factor: 5.948

5.  Burkholderia cepacia produces a hemolysin that is capable of inducing apoptosis and degranulation of mammalian phagocytes.

Authors:  M L Hutchison; I R Poxton; J R Govan
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

Review 6.  Aerosol antibiotic treatment in cystic fibrosis.

Authors:  J M Littlewood; S W Smye; H Cunliffe
Journal:  Arch Dis Child       Date:  1993-06       Impact factor: 3.791

7.  Field inversion gel electrophoresis on Pseudomonas cepacia strains isolated from cystic fibrosis patients.

Authors:  G Amalfitano; E Tonolli; F Favari; C Perazzoli; G Cazzola; G Mastella; I Piacentini
Journal:  Eur J Epidemiol       Date:  1996-04       Impact factor: 8.082

8.  Pulmonary evolution of cystic fibrosis patients colonized by Pseudomonas aeruginosa and/or Burkholderia cepacia.

Authors:  I Jacques; J Derelle; M Weber; M Vidailhet
Journal:  Eur J Pediatr       Date:  1998-05       Impact factor: 3.183

9.  Epidemic of Pseudomonas cepacia in an adult cystic fibrosis unit: evidence of person-to-person transmission.

Authors:  D L Smith; L B Gumery; E G Smith; D E Stableforth; M E Kaufmann; T L Pitt
Journal:  J Clin Microbiol       Date:  1993-11       Impact factor: 5.948

10.  Nosocomial acquisition of Pseudomonas aeruginosa by cystic fibrosis patients.

Authors:  B Tümmler; U Koopmann; D Grothues; H Weissbrodt; G Steinkamp; H von der Hardt
Journal:  J Clin Microbiol       Date:  1991-06       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.